Skip to main content

Table 1 Patient and tumour characteristics

From: Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

 

Number

Percent

Tumour size

 ≤50 mm

613

80.1

 >50 mm

152

19.9

 Total

765

100

Node status

 Negative

388

50.7

 Positive

377

49.3

 Total

765

100

Grade

 1

22

2.9

 2

245

32

 3

328

42.9

 Missing

170

22.2

 Total

765

100

Taxane sequence

 Taxane first

387

50.6

 Taxane second

378

49.4

 Total

765

100

pCR

 No pCR

633

82.7

 pCR

122

15.9

 Missing

10

1.3

 Total

765

100

ER, HER2 status

 ER–, HER2–

152

19.9

 ER–, HER2+

64

8.4

 ER+, HER2–

342

44.7

 ER+, HER2+

116

15.2

 Missing

91

11.9

 Total

765

100

Diagnostic biopsies

 Missing

142

18.6

 Analysed

623

81.4

 Total

765

100

Surgical samples

 Missing

66

8.6

 Analysed

699

91.4

 Total

765

100

  1. pCR pathological complete response, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2